Skip to main content

eFFECTOR Therapeutics, Inc. (EFTR)

NASDAQ: EFTR · Delayed Price · USD
7.37
1.66 (29.07%)
At close: Dec 6, 2021 4:00 PM
7.60
0.23 (3.12%)
Pre-market:Dec 7, 2021 8:28 AM EST
Market Cap297.54M
Revenue (ttm)1.12M
Net Income (ttm)-3.25M
Shares Out40.37M
EPS (ttm)-0.10
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume561,008
Open5.81
Previous Close5.71
Day's Range5.66 - 7.87
52-Week Range5.50 - 40.42
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About EFTR

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to tre...

IndustryBiotechnology
Founded2012
CEOSteve Worland
CountryUnited States
Stock ExchangeNASDAQ
Ticker SymbolEFTR
Full Company Profile

Financial Performance

Financial Statements

News

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven Tumors Study Demonstrates Role of Zotatifin in Blocking Tumor Growth in Receptor Tyrosine Kinase Driven T...

1 week ago - GlobeNewsWire

eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs)...

2 weeks ago - GlobeNewsWire

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

•   Continuing to enroll patients in Phase 2b KICKSTART study of tomivosertib in combination with pembrolizumab, a U.S. Food and Drug Administration (FDA) approved PD-1 inhibitor

4 weeks ago - GlobeNewsWire

eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today an...

1 month ago - GlobeNewsWire

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today an...

1 month ago - GlobeNewsWire

eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer

eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zotatifin in animal models of triple-negative breast cance...

1 month ago - Benzinga

Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin...

• Demonstrated statistically significant anti-tumor activity and inhibited proliferative and stem-cell signaling pathways

1 month ago - GlobeNewsWire

Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Co...

SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today a...

2 months ago - GlobeNewsWire

Hold Off on eFFECTOR Therapeutics if You Can't Stomach the Risk

While EFTR stock has escaped the usual underperformance of SPAC IPOs so far, eFFECTOR Therapeutics still remains a risky proposition. The post Hold Off on eFFECTOR Therapeutics if You Can't Stomach the ...

2 months ago - InvestorPlace

eFFECTOR Therapeutics Stock Might Be Worth the Risk in Small Quantities

During the post-SPAC spectacle, EFTR stock be volatile - this should be expected. Still, eFFECTOR's oncology therapies look promising.

2 months ago - InvestorPlace

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today a...

2 months ago - GlobeNewsWire

What's Going On With eFFECTOR Therapeutics Stock Today?

eFFECTOR Therapeutics Inc (NASDAQ: EFTR) is trading higher Monday after Cantor Fitzgerald initiated coverage on the stock. Cantor Fitzgerald analyst Louise Chen initiated coverage on eFFECTOR Therapeuti...

2 months ago - Benzinga

Why eFFECTOR Therapeutics Stock Is Heating Up Today

The biotech's novel cancer platform is fueling buyout speculation on social media today.

2 months ago - The Motley Fool

EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up 100%

Here's what investors may want to know about eFFECTOR and EFTR stock, as the company's shares surge once again today in a big way. The post EFTR Stock: 7 Things to Know About eFFECTOR as Shares Shoot Up...

2 months ago - InvestorPlace

EFTR Stock: What Is Going on With Red-Hot eFFECTOR Therapeutics Today?

After a tough week for SPACs, EFTR stock has enjoyed significant gains today. The SPAC bubble may not be over yet.

2 months ago - InvestorPlace

eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New C...

Common stock and warrants expected to commence trading on Nasdaq on August 26, 2021 under the ticker symbols EFTR and EFTRW Common stock and warrants expected to commence trading on Nasdaq on August 26,...

3 months ago - GlobeNewsWire

LWAC Stock: eFFECTOR Therapeutics SPAC Merger News Sends Shares Skyrocketing

Locust Walk Acquisition (LWAC) stock is rocketing higher on Wednesday following news that it can move forward with the eFFECTOR Therapeutics. The post LWAC Stock: eFFECTOR Therapeutics SPAC Merger News ...

3 months ago - InvestorPlace

Why Is This SPAC Surging 160% Today?

Shares of Locust Walk Acquisition Corp (NASDAQ: LWAC) are surging higher Wednesday morning after the merger with eFFECTOR Therapeutics was approved. eFFECTOR Therapeutics is focused on selective transla...

3 months ago - Benzinga

eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Gen...

SAN DIEGO, May 27, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a biopharmaceutical company focused on pioneering the development of selective translation regulation inhibitors (STRI...

6 months ago - GlobeNewsWire

EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline

A biotechnology company using selective tranlsation regulation inhibitors to treat cancer is going public in a SPAC deal.  The SPAC Deal: eFFECTOR Therapeutics will merge with Locust Walk Acquisition Co...

6 months ago - Benzinga